The CSL Ltd ( ASX: CSL ) share price has fallen to its lowest level in almost a decade.

On Monday, shares in the biotech giant dropped to $140.93, marking the lowest level since December 2017.

At the time of writing, the CSL share price has edged slightly higher to $141.30, though it remains down 3.40% for today.

The decline caps off a difficult period for investors. CSL shares have now fallen more than 20% over the past month and are down roughly 45% over the past year.

This makes it one of the weakest performers among ASX healthcare heavyweights.

Investor sentiment turns bearish

One major factor behind the weakness appears to be a major shift in investor sentiment.

CSL was once widely viewed as one of the ASX's most dependable growth companies. However, recent years have been more challenging. Earnings growth has slowed, and several operational pressures have weighed on the company's outlook.